While there is not much controversy in stating APOE4 increases the risk of AD by driving earlier and more abundant amyloid pathology in the brains of APOE4 carriers [30], the work of Lazar et al. [76] in mice expressing the human APOE4 vs. APOE3 isoform shows APOE4 carriers had altered cholesterol turnover, ratio imbalances of specific classes of phospholipids, low phosphatidylethanolamines bearing polyunsaturated fatty acids, and an elevation in monounsaturated fatty acids. This evidence concerns the gene APOE and Alzheimer disease.